SLDB Q3 2020 Earnings — Solid Biosciences Inc. Revenue & Financial Results | Market Cap Arena

SLDBSolid Biosciences Inc.

$581M

Q3 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$21M

Net Income

-$21M

EPS (Diluted)

$-6.60

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$16M

Free Cash Flow

-$16M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$41M

Total Liabilities

$18M

Stockholders' Equity

$22M

Cash & Equivalents

$25M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$21M	-$30M	+28.6%
Net Income	-$21M	-$29M	+27.4%